Prognostic significance of soluble interleukin-2 receptor levels in patients with dilated cardiomyopathy

European Journal of Clinical Investigation

Volumn 33, Issue 6, 2003, Pages 443-448

  Limas, Constantinos J ^a   Hasikidis, C ^a   Iakovou, J ^a   Kroupis, C ^a   Haidaroglou, A ^a   Cokkinos, D V ^a  

^a ONASSIS CARDIAC SURGERY CENTER   (Greece)

Author keywords

Dilated cardiomyopathy; HLA DQ; Lymphocyte proliferation; Soluble interleukin 2 receptors; T lymphocytes

Indexed keywords

CONCANAVALIN A; HISTIDINE; HLA DQB1 ANTIGEN; INTERLEUKIN 2 RECEPTOR; THYMIDINE;

ADULT; ARTICLE; CONTROLLED STUDY; DEATH; DISEASE COURSE; DISEASE EXACERBATION; ECHOCARDIOGRAPHY; FEMALE; GENOTYPE; HEART DILATATION; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HEART TRANSPLANTATION; HEART VENTRICLE ENDDIASTOLIC PRESSURE; HUMAN; HUMAN CELL; ISCHEMIC HEART DISEASE; LYMPHOCYTE PROLIFERATION; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL;

CARDIOMYOPATHY, DILATED; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; RECEPTORS, INTERLEUKIN-2; SEVERITY OF ILLNESS INDEX; SOLUBILITY; T-LYMPHOCYTES;

EID: 0038575770     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2362.2003.01111.x     Document Type: Article

References (22)

1. Smith SC, Allen PM. Myosin induced myocarditis is a T cell-mediated disease. J Immunol 1991;147:2141-7.
2. Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 1990;223:236-41.
3. Torre-Amione G, Kapadia S, Benedict C, Oral H, Young JB, Mann DL. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction. a report from the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol 1996;27:1201-6.
4. Kelly RA, Smith TW. Cytokines and cardiac contractile function. Circulation 1997;95:778-81.
5. Kuhl U, Noutsias M, Seeberg B, Schultheiss HP. Immunohistological evidence for a chronic intramyocardial inflammatory process in dilated cadiomyopathy. Heart 1996;75:295-300.
6. Holzinger C, Schollhammer A, Imhof M, Reinwald C, Kramer G, Zuckermann A et al. Phenotypic patterns of mononuclear cells in dilated cardiomyopathy. Circulation 1995;92:2876-85.
7. Limas CJ, Goldenberg IF, Limas C. Soluble interleukin-2 receptor levels in patients with dilated cardiomyopathy. Circulation 1995;91:631-4.
8. Samsonov M, Wachter H, Fuchs D. Serum soluble interleukin-2 receptor, neopterin levels, and severity of dilated cardiomyopathy. Circulation 1996;93:1255-6.
9. Richardson P, Mckenna W, Bristow M, Maisch B, Mautner B, O'Connell J et al. Report of the 1995 World Health Organization/International Society and Federation of Cardiology task force on the definition and classification of cardiomyopathies. Circulation 1996;93:841-2.
10. Mittal K, Mickey MR, Singal DP, Terasaki PI. Serotyping for homotransplantation. Transplant 1968;6:913-6.
11. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucl Acids Res 1988;16:1215.
12. El-Demellawy M, El-Ridi R, Guirguis NI, Alim MA, Kotby A, Kotb M. Preferential recognition of human myocardial antigens by T lymphocytes from rheumatic heart disease patients. Infect Immunol 1997;65:2197-205.
13. Theze J, Alzari PM, Bertoglio J. Interleukin 2 and its receptors. recent advances and new immunological functions. Immunol Today 1996;17:481-6.
14. Matsumori A, Yamada T, Suzuki H, Matoba Y, Sasayama S. Increased circulating cytokines in patients with myocarditis and cardiomyopathy. Br Heart J 1994;72:651-5.
15. Munger MA, Johnson B, Amber JJ, Callahan KS, Gilbert EM. Circulating concentrations of proinflammatory cytokines in mild or moderate heart failure secondary to ischaemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1996;77:723-77.
16. Kanda T, Yokohama T, Ohshima S, Yucisa K, Watanabe T, Suzuki T et al. T-lymphocyte subsets as noninvasive markers of cardiomyopathy. Clin Cardiol 1990;13:2617-22.
17. Harris TJ, Waltman TS, Carter SM, Maisel AS. Effect of prolonged catecholamine infusion on immunoregulatory function: implications in congestive heart failure. J Am Coll Cardiol 1995;26:102-9.
18. Bromelow LV, Souberbielle B, Alavi A, Goldman JH, Libera LD, Dalgleish AG et al. Lack of T-cell response to cardiac myosin and a reduced response to PPD in patients with idiopathic dilated cardiomyopathy. J Autoimmun 1997;10:219-27.
19. Mason JW, O'Connell JS, Herskowitz A, Rose NR, McManus BM, Billingham ME et al. A clinical trial of immunosuppressive therapy for myocarditis. N Engl J Med 1995;333:269-75.
20. Goebel J, Stevens E, Forrest K, Rossman TL. Dalizumab (Zenapax) inhibits early interleukin-2 receptor signal transaction events. Transpl Immunol 2000;8:153-9.
21. McNamara DM, Holubkov R, Starling RC, Dec GW, Loh E, Torre-Amione G et al. Controlled trial of intravenous immune globulin in recent-onset dilated cardiomyopathy. Circulation 2001;103:2254-9.
22. Petrovsky N, Harrison LC. HLA class II-associated polymorphism of interferon-gamma production. Implications for HLA-disease association. Hum Immunol 1997;53:12-6.